Literature DB >> 16959453

Rapid-onset intranasal delivery of metoclopramide hydrochloride Part II: Safety of various absorption enhancers and pharmacokinetic evaluation.

N M Zaki1, N D Mortada, G A S Awad, S S Abd ElHady.   

Abstract

In the present study, several nasal absorption enhancers, used in metoclopramide hydrochloride (MCP HCl) nasal solutions, have been screened for their possible damaging effect in the in vitro human erythrocytes lysis experiment. Moreover, the in vivo leaching of biological markers from the rat nasal epithelium was used as a quantitative assessment for possible nasal mucosal irritation whereby the extent of release of total protein and lactate dehydrogenase (LDH) in the nasal lavage fluid was determined. Results showed that insignificant hemolysis from normal saline (P<0.05) occurred with the enhancer protamine sulphate while poly-l-arginine and sodium cholate demonstrated very low (<15%) hemolysis and caused insignificant protein and LDH release from the rat nasal mucosa. Conversely, sodium deoxycholate and chitosan polymers (either of low or high molecular weight) showed high (>60%) hemolysis in vitro and the release of the biological markers in vivo was significantly higher (P<0.05) than the control solution (no enhancer). A significant correlation (P<0.05) existed between the enhancement effect of MCP HCl nasal absorption and the amounts of protein (r=0.85) and LDH (r=0.88). Furthermore, the pharmacokinetics of MCP HCl was determined after intravenous (IV), per-oral and intranasal administration of 10mg drug dose in rabbits. The application of a nasal spray (NS) solution containing 0.5% sodium cholate resulted in a significant improvement (P<0.05) in both the rate and extent of absorption of MCP HCl where the T(max) achieved was 23.3min as compared to 50min in case of the oral solution while the area under the serum concentration-time curve (AUC(0-infinity)) were 506.1, 434.9 and 278.7microg/mlmin for IV, NS and oral solutions, respectively. These values corresponded to absolute bioavailabilities of 87.21 and 55.61% for the NS and oral solutions, respectively. It could thus be concluded that NS of MCP HCl represents a viable approach to achieving rapid and high systemic drug absorption during the emergency treatment of severe emesis.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16959453     DOI: 10.1016/j.ijpharm.2006.07.038

Source DB:  PubMed          Journal:  Int J Pharm        ISSN: 0378-5173            Impact factor:   5.875


  6 in total

1.  Enhanced antibacterial effect of ceftriaxone sodium-loaded chitosan nanoparticles against intracellular Salmonella typhimurium.

Authors:  Noha M Zaki; Mohamed M Hafez
Journal:  AAPS PharmSciTech       Date:  2012-02-23       Impact factor: 3.246

2.  Complexation of a poly-L-arginine with low molecular weight heparin enhances pulmonary absorption of the drug.

Authors:  Amit Rawat; Tianzhi Yang; Alamdar Hussain; Fakhrul Ahsan
Journal:  Pharm Res       Date:  2007-10-23       Impact factor: 4.200

3.  Detection of multiple globin monoadducts and cross-links after in vitro exposure of rat erythrocytes to S-(1,2-dichlorovinyl)-L-cysteine sulfoxide and after in vivo treatment of rats with S-(1,2-dichlorovinyl)-L-cysteine sulfoxide.

Authors:  Nella Barshteyn; Adnan A Elfarra
Journal:  Chem Res Toxicol       Date:  2008-08-06       Impact factor: 3.739

4.  Mechanisms of deformable nanovesicles based on insulin-phospholipid complex for enhancing buccal delivery of insulin.

Authors:  You Xu; Xing Zhang; Yun Zhang; Jun Ye; Hong-Liang Wang; Xuejun Xia; Yuling Liu
Journal:  Int J Nanomedicine       Date:  2018-11-09

Review 5.  Nasally inhaled therapeutics and vaccination for COVID-19: Developments and challenges.

Authors:  Jinxiang Xi; Lameng Ray Lei; William Zouzas; Xiuhua April Si
Journal:  MedComm (2020)       Date:  2021-12-14

6.  Short Onset and Enhanced Analgesia Following Nasal Administration of Non-Controlled Drugs in Nanovesicular Systems.

Authors:  Elka Touitou; Hiba Natsheh; Shatha Boukeileh; Rania Awad
Journal:  Pharmaceutics       Date:  2021-06-28       Impact factor: 6.321

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.